American Capital Management’s Meridian Bioscience Inc VIVO Stock Holding History

American Capital Management’s Portfolio VIVO Stock Details VIVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-16,760	Closed	-$231K	–	85
2017 Q1	$231K	Sell	16,760 -1,500	-8%	-$21K	0.02%	79
2016 Q4	$323K	Sell	18,260 -24,250	-57%	-$426K	0.03%	86
2016 Q3	$820K	Buy	+42,510	New	+$832K	0.06%	80
2016 Q2	–	Sell	-48,450	Closed	-$999K	–	166
2016 Q1	$999K	Sell	48,450 -5,500	-10%	-$108K	0.09%	83
2015 Q4	$1.11M	Sell	53,950 -4,200	-7%	-$80.5K	0.1%	81
2015 Q3	$994K	Sell	58,150 -800	-1%	-$14.6K	0.1%	60
2015 Q2	$1.1M	Hold	58,950	–	–	0.1%	63
2015 Q1	$1.13M	Hold	58,950	–	–	0.11%	61
2014 Q4	$970K	Sell	58,950 -73,100	-55%	-$1.25M	0.11%	60
2014 Q3	$2.34M	Hold	132,050	–	–	0.27%	50
2014 Q2	$2.73M	Hold	132,050	–	–	0.31%	51
2014 Q1	$2.88M	Buy	132,050 +6,000	+5%	+$138K	0.34%	53
2013 Q4	$3.34M	Hold	126,050	–	–	0.41%	49
2013 Q3	$2.98M	Hold	126,050	–	–	0.4%	53
2013 Q2	$2.71M	Buy	+126,050	New	+$2.72M	0.41%	54

Other funds holding VIVO

BCM

Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

American Capital Management's VIVO Position: Q2 2017 in Review

American Capital Management sold out of Meridian Bioscience Inc (VIVO) in Q2 2017, closing a stake of 16,760 shares — an estimated $231K sold.

American Capital Management first reported a position in VIVO in Q2 2013 and held it in 15 quarters. The position peaked at $3.34M in Q4 2013. 170 funds tracked by Wall St. Rank hold VIVO as of Q2 2017.

American Capital Management reported no remaining Meridian Bioscience Inc position as of Q2 2017 after selling out during the quarter.
American Capital Management sold 16,760 Meridian Bioscience Inc shares in Q2 2017, an estimated $231K.
American Capital Management first reported a position in Meridian Bioscience Inc in Q2 2013 and held it in 15 quarters.
American Capital Management's Meridian Bioscience Inc position peaked at $3.34M in Q4 2013.
170 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q2 2017.

Based on American Capital Management's 13F filing for Q2 2017, filed 27 Jul 2017.